Jim Simons’s Virax Biolabs VRAX Stock Holding History

Jim Simons’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,816	Closed	-$282K	–	3944
2024 Q3	$282K	Buy	5,816 +5,376	+1,222%	+$309K	﹤0.01%	3003
2024 Q2	$12.8K	Buy	+440	New	+$10.9K	﹤0.01%	3408
2023 Q3	–	Sell	-98	Closed	-$10K	–	4149
2023 Q2	$10K	Buy	+98	New	+$10.8K	﹤0.01%	3828
2023 Q1	–	Sell	-46	Closed	-$8K	–	4438
2022 Q4	$8K	Buy	+46	New	+$16.3K	﹤0.01%	4046

Other funds holding VRAX

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jim Simons's VRAX Position: Q4 2024 in Review

Jim Simons sold out of Virax Biolabs (VRAX) in Q4 2024, closing a stake of 5,816 shares — an estimated $282K sold.

Jim Simons first reported a position in VRAX in Q4 2022 and held it in 4 quarters. The position peaked at $282K in Q3 2024. 6 funds tracked by Wall St. Rank hold VRAX as of Q4 2024.

Jim Simons reported no remaining Virax Biolabs position as of Q4 2024 after selling out during the quarter.
Jim Simons sold 5,816 Virax Biolabs shares in Q4 2024, an estimated $282K.
Jim Simons first reported a position in Virax Biolabs in Q4 2022 and held it in 4 quarters.
Jim Simons's Virax Biolabs position peaked at $282K in Q3 2024.
6 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.